Akebia Therapeutics Inc (NASDAQ: AKBA) on Friday, soared 2.76% from the previous trading day, before settling in for the closing price of $2.54. Within the past 52 weeks, AKBA’s price has moved between $0.80 and $2.90.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -10.63% over the last five years. The company achieved an average annual earnings per share of 68.48%. With a float of $251.86 million, this company’s outstanding shares have now reached $261.64 million.
The firm has a total of 181 workers. Let’s measure their productivity. In terms of profitability, gross margin is 67.77%, operating margin of -11.91%, and the pretax margin is -24.51%.
Akebia Therapeutics Inc (AKBA) Breakdown of a Key Holders of the stock
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Akebia Therapeutics Inc is 4.10%, while institutional ownership is 36.57%. The most recent insider transaction that took place on Mar 03 ’25, was worth 84,928. In this transaction CEO and President of this company sold 46,409 shares at a rate of $1.83, taking the stock ownership to the 2,557,921 shares. Before that another transaction happened on Mar 03 ’25, when Company’s SVP, Chief Medical Officer sold 7,144 for $1.83, making the entire transaction worth $13,074. This insider now owns 809,090 shares in total.
Akebia Therapeutics Inc (AKBA) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.05 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 68.48% per share during the next fiscal year.
Akebia Therapeutics Inc (NASDAQ: AKBA) Trading Performance Indicators
Akebia Therapeutics Inc (AKBA) is currently performing well based on its current performance indicators. A quick ratio of 2.02 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.71.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.22, a number that is poised to hit -0.02 in the next quarter and is forecasted to reach 0.02 in one year’s time.
Technical Analysis of Akebia Therapeutics Inc (AKBA)
Analysing the last 5-days average volume posted by the [Akebia Therapeutics Inc, AKBA], we can find that recorded value of 4.21 million was better than the volume posted last year of 3.75 million. As of the previous 9 days, the stock’s Stochastic %D was 43.59%. Additionally, its Average True Range was 0.16.
During the past 100 days, Akebia Therapeutics Inc’s (AKBA) raw stochastic average was set at 78.99%, which indicates a significant increase from 55.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.95% in the past 14 days, which was lower than the 94.25% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.13, while its 200-day Moving Average is $1.82. Now, the first resistance to watch is $2.66. This is followed by the second major resistance level at $2.70. The third major resistance level sits at $2.77. If the price goes on to break the first support level at $2.55, it is likely to go to the next support level at $2.48. Now, if the price goes above the second support level, the third support stands at $2.44.
Akebia Therapeutics Inc (NASDAQ: AKBA) Key Stats
Market capitalization of the company is 685.48 million based on 262,636K outstanding shares. Right now, sales total 160,180 K and income totals -69,410 K. The company made 57,340 K in profit during its latest quarter, and 6,110 K in sales during its previous quarter.
